PharmaMar
Manufacturing · Spain · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
Avda. De Los Reyes 1pol, Colmenar Viejo,...Phone Number
+34 918466000Website
www.pharmamar.comRevenue
$171.4 MillionStock Symbol
PHMIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About PharmaMar
Founded in 1986, PharmaMar a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, the rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and ovarian cancer; and Aplidin for treating multiple myeloma. The company also develops clinical-stage programs, including Lurbinectedin, PM184, and PM14. Also, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company is headquartered in Madrid, Spain.Explore more
PharmaMar Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PharmaMar your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if PharmaMar has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once PharmaMar has new funding data
Earning: See what the market has to say on PharmaMar recently announced quarterly report
PharmaMar, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if PharmaMar is spiking on competitors!
Click to see if PharmaMar had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at PharmaMar
Product Launch: Get notified when PharmaMar launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
PharmaMar is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
PharmaMar is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about PharmaMar.
PharmaMar Tech Stack
A closer look at the technologies used by PharmaMar
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Product Marketing, Events, Training, Medical Research, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Technology
Event
Product Marketing, Events, Software, Field /Outside Sales, Field Marketing, Healthcare Operations, Healthcare Technology
PharmaMar News & Media
PharmaMar looks to accelerate oncology research with AI through collaboration with Globant
The new alliance has launched a multi-agent AI framework to support faster, data-driven decisions in cancer research. Agentic AI system achieves 15x faster insights with over 90% accuracy. MADRID, March 19, 2026 /PRNewswire/ -- Globant (NYSE: GLOB), a digitally native company that helps...PharmaMar presents at ASCO that the Zepzelca®(lurbinectedin) and atezolizumab (Tecentriq®) combination significantly improves survival as first-line maintenance therapy for extensive-stage small cell lung cancer
First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from the point of randomization First Phase 3 study to demonstrate statistically significant and...PharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Jazz plans to submit supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and PharmaMar will submit Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in first half of the year 2025 for this combination therapy as a...Spanish Pharma Companies Boost Profits to Over 150 Million Euros by June - Born2Invest
According to the results presented by the pharmaceutical giants to the National Securities Commission (CNMV), the revenues of these five companies also rose in the first half of the year, although with a more moderate growth than profits. Rovi was the only listed Spanish pharmaceutical company to see its revenues fall in the first six months, recording a year-on-year drop of 13.5%.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding PharmaMar
Sign Up For FreeTo access detailed company insights
Founded in 1986, PharmaMar a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, the rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and com... Read More
